Covered recipient · General Payments record
CAITLIN LEIGH NEUKIRCH
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$1,043.44
- Reported across 59 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $272.71 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $65.57 | 4 |
| Exact Sciences Corporation | $46.58 | 3 |
| Novo Nordisk AS | $33.00 | 2 |
| Astellas Pharma US Inc | $30.50 | 1 |
| Xeris Pharmaceuticals, Inc. | $23.71 | 1 |
| Merck Sharp & Dohme Corporation | $17.35 | 1 |
| Lilly USA, LLC | $14.62 | 1 |
| PFIZER INC. | $14.48 | 1 |
| GlaxoSmithKline, LLC. | $13.52 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.38 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.62 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107729600 | CMS |
| ABBVIE INC. | $13.81 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107729602 | CMS |
| ABBVIE INC. | $19.49 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107729604 | CMS |
| ABBVIE INC. | $17.65 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107729606 | CMS |
| Astellas Pharma US Inc | $30.50 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139494808 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.38 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086339927 | CMS |
| Exact Sciences Corporation | $14.34 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114506390 | CMS |
| Exact Sciences Corporation | $16.27 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114506396 | CMS |
| Exact Sciences Corporation | $15.97 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114506402 | CMS |
| GlaxoSmithKline, LLC. | $13.52 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116703654 | CMS |
| Lilly USA, LLC | $14.62 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135571895 | CMS |
| Merck Sharp & Dohme LLC | $17.35 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141850230 | CMS |
| Novo Nordisk Inc | $13.89 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100580508 | CMS |
| Novo Nordisk Inc | $19.11 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100651241 | CMS |
| PFIZER INC. | $14.48 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131125682 | CMS |
| Xeris Pharmaceuticals, Inc. | $23.71 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144622114 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.